X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

International Institute for Integrative Sleep Medicine (WPI-IIIS, University of Tsukuba, Japan) announces drug discovery collaboration agreement with Merck

Yuvraj_pawp by Yuvraj_pawp
19th November 2015
in Americas, News

International Institute for Integrative Sleep Medicine, University of Tsukuba (“WPI-IIIS”) today announced a research collaboration agreement with Merck & Co., Inc.,

Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada. Under the agreement, WPI-IIIS and Merck will perform collaborative research aimed at discovering new medicines for disorders of the central nervous system. This is the first significant collaborations for the University of Tsukuba with an overseas company.

“I am very pleased to establish this collaborative research agreement with Merck. By combining the basic research conducted in our institute and the drug discovery expertise at Merck, we hope to deliver new medicines to the patients,” said Masashi Yanagisawa, director of WPI-IIIS.

Based on the agreement, Yanagisawa, Hiroshi Nagase (principal investigator of WPI-IIIS) and their colleagues will conduct drug discovery in collaboration with central nervous system researchers at Merck.

The collaboration will also encourage interactions between scientists involved in the field of drug discovery, accelerating the exploration of new treatment options for disorders of the central nervous system.

Tags: America
Previous Post

Proteros signs new oncology collaboration with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA on epigenetic target

Next Post

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Related Posts

Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
News

Types of Pharmaceutical Waste and How to Dispose of Them

31st December 2024
Developing Pharma Skills With Life Sci For Growth Initiative
News

UK Medicine Manufacturing Regulatory Framework For Care

6th November 2024
News

Nanoemulsion Drug Delivery Enhances Tuberculosis Care

6th November 2024
News

The Future of Drug Delivery Systems In Modern Medicine

6th November 2024
Next Post

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In